Skip to content
Serum Institute of India
-
Oxford launches first human trial of Bundibugyo Ebola vaccine as DRC outbreak intensifies
The BD-Ebov trial, which is being conducted in Oxford, will evaluate the safety, tolerability and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged between 18 and 55 years.
-
CEPI pledges US$60M to fast-track Bundibugyo Ebola vaccines from Moderna, Oxford, and IAVI
The funding will support three promising vaccine candidates being developed by Moderna, the University of Oxford in partnership with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).
-
Bavarian Nordic partners with Serum Institute of India to boost Chikungunya vaccine production
This arrangement strengthens an existing partnership between the two pharmaceutical giants, who already collaborate on manufacturing the mpox vaccine.
-
Valneva terminates Asia vaccine partnership with Serum Institute of India
The collaboration aimed to support the distribution of Valneva’s single-dose vaccine, Ixchiq, in low- and middle-income countries (LMICs) across Asia.